Iodomethane

Iodomethane

SCHEMBL87147

[2H]CI

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodomethane SCHEMBL118500 0.83
Iodomethane SCHEMBL799995 0.83
Iodomethane SCHEMBL28473371 0.77
Iodomethane SCHEMBL3415879 0.72
Ethane SCHEMBL29691387 0.55
Ethane SCHEMBL1331172 0.55
Ethane SCHEMBL4877482 0.55
Ethane SCHEMBL18184927 0.55
Ethane SCHEMBL21175041 0.55
Methylamine SCHEMBL1332656 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1079 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115920785-A Catalytic production equipment for deuterated iodomethane 山东法拉第氘源科技有限公司 2023-04-07 CN claimed
CN-113582976-B Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof 郑州大学 2023-03-17 CN claimed
CN-113582976-A Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof 郑州大学 2021-11-02 CN claimed
CN-113493466-A Stable isotope labeled ofloxacin and synthetic method thereof 上海安谱实验科技股份有限公司 2021-10-12 CN claimed
US-12622917-B2 High-activity Wnt pathway inhibitor compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-05-12 US disclosed
US-12612383-B2 Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof SHANGHAI WENNAI THERAPEUTICS CO., LTD. (CN) 2026-04-28 US disclosed
US-20260022100-A1 NAV1.8 INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2026-01-22 US disclosed
US-20250325557-A1 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE WISTA LABORATORIES LTD. (SG) 2025-10-23 US disclosed
US-20250296922-A1 POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI WENNAI THERAPEUTICS CO LTD (CN) 2025-09-25 US disclosed
US-20250230128-A1 DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE CYBIN IRL LIMITED (IE) 2025-07-17 US disclosed
EP-4585599-A1 NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) 2025-07-16 EP disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
US-7157456-B2 Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer BAYER HEALTHCARE AG (DE) 2007-01-02 US disclosed
US-7157451-B2 Heterocyclic dihydropyrimidine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-7157469-B2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same AVANIR PHARMACEUTICALS (US) 2007-01-02 US disclosed
EP-1729814-A2 PEGYLATED ION CHANNEL MODULATING COMPOUNDS Cardiome Pharma Corp. (CA) 2006-12-13 EP disclosed
US-20060276408-A1 Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins MYRIAD GENETICS, INCORPORATED (US) 2006-12-07 US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 US disclosed
WO-2005094897-A2 PEGYLATED ION CHANNEL MODULATING COMPOUNDS CARDIOME PHARMA CORP. (CA) 2005-10-13 WO disclosed
US-20040102472-A1 Method of preparing inhibitors of phosphodiesterase-4 MERCK & CO., INC. 2004-05-27 US disclosed